Annals of Clinical Biochemistry > Volume 45, Number 6 > Pp. 598-600

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: acb.2008.008074v1 45/6/598    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barth, J. H Articles by Sibley, P. E C Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Short Reports

Standardization of the IMMULITE systems growth hormone assay with the recombinant IS 98/574

Julian H Barth¹ and Paul E C Sibley²

¹ Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds LS1 3EX; ² Siemens Healthcare Diagnostics, Glyn Rhonwy, Llanberis LL55 4EL, UK

Corresponding author: Dr Julian H Barth. Email: julian.barth{at}leedsth.nhs.uk

Background: The diagnosis of disorders of growth hormone (GH) secretion is based on the measurement of GH before and after dynamic stimulation or suppression tests. Over the years, specific cut-off values have been proposed without taking account of the considerable variation in results obtained using different methods for analysing GH. Recent publications have recommended the standardization of GH assays using IS 98/574, which is calibrated in mass and units (U). The IMMULITE range of GH assays have been recalibrated using this standard.

Methods: We analysed 745 samples using the current and the restandardized GH assay kits. This series of samples contained 90 stimulation tests and seven suppression tests.

Results: The data comparing the current and restandardized assays show a similar relationship for both basal and stimulated GH values for all IMMULITE platforms. There is a negative bias by the restandardized assay above approximately 20 µg/L. A conversion can be derived from this study which would mean that patient GH results expressed in milliunits per litre of IMMULITE in-house derived standard will be approximately three-fold of that expressed in micrograms per litre of IS 98/574.

Conclusion: Use of IS 98/574 offers standardized reporting in microgram per litre IS 98/574. This will permit compliance with the consensus recommendations and the development of a firm evidence base for defining decision-making GH values.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Secco, N. di Iorgi, F. Napoli, E. Calandra, A. Calcagno, M. Ghezzi, C. Frassinetti, N. Fratangeli, S. Parodi, M. Benassai, et al. Reassessment of the Growth Hormone Status in Young Adults with Childhood-Onset Growth Hormone Deficiency: Reappraisal of Insulin Tolerance Testing J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4195 - 4204. [Abstract] [Full Text] [PDF]